Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals
Article Abstract:
A high rate of dropouts in trials of AIDS drugs could lead to an underestimation or overestimation of the drugs' effects. Researchers analyzed CD4 cell counts in 245 HIV-infected people enrolled in a trial comparing zidovudine (AZT) and didanosine (ddI). Only half the participants completed the 48-week study. Participants with lower CD4 counts were more likely to drop out. More people taking zidovudine dropped out due to side effects. Various methods were used to estimate the CD4 counts of the people who dropped out assuming they had remained in the study. At various times throughout the study, the CD4 counts of those who dropped out were estimated to be lower than the counts of those who remained in the study. The average change in CD4 count was also greater in those who dropped out. This indicates that the treatment would be assumed to have a greater effect than it actually did.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004)
Article Abstract:
Retrospective cohort study is used to evaluate the temporal patterns of antiretroviral (ARV) prescribing practices that are relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection. The results have shown that the U.S. department of Veterans Affairs (VA) prescribing patterns for ARV initiation has followed the treatment guidelines that maximize safety.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials
Article Abstract:
HIV patients who do not initially respond to triple combination therapy may eventually respond. On the other hand, patients on double combination therapy who do respond initially may relapse and those who do not respond may never respond.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Ethical considerations in the treatment of infertility in women with human immunodeficiency virus infection. In treating infertility, are multiple pregnancies unavoidable?
- Abstracts: Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. Cognitive function in HIV-1-infected drug users
- Abstracts: Fetal electrocardiography in labor and neonatal outcome: data from the Swedish randomized controlled trial on intrapartum fetal monitoring
- Abstracts: HPV vaccine moves into late stage trials. South African village prepares for first HIV vaccine trial... Hepatitis C virus and eliminating post-transfusion hepatitis
- Abstracts: Who is to blame for obesity crisis? Testing, testing: how the new pediatric drug trials may affect your child